Upjohn | Search

Trials

24 participants · First posted Apr 1, 2008

Completed

NCT00913341

To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg

30 participants · First posted Jun 4, 2009

Completed

NCT00647634

Fasting Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg

21 participants · First posted Apr 1, 2008

Drugs

View all 6 →

Biotech

Investigational

Nerve Growth Factor

Rx

Biotech

Approved

Mecasermin(Increlex)

Conditions: Primary Insulin-like Growth Factor-1 Deficiency

Small Molecule

Approved

Alprazolam(Niravam, Xanax)

Manufacturer: Roxane laboratories inc, Actavis elizabeth llc +21 more

Conditions: Generalized Anxiety Disorder, Panic Disorder

C₁₇H₁₃ClN₄ · Rx

Organizations

View all 45 →

Upjohn EESV

Netherlands

Pharmacia & Upjohn, S.A.

Guatemala

UpJohn US 2 LLC

United States

News

View all 29 →

last year

Gland Pharma Receives US FDA Approval for Latanoprost Ophthalmic Solution

last year

Strides Pharma Secures USFDA Approval for Celecoxib Capsules, Targeting $116M Market

last year

Trials

Fasting Study of Alprazolam Extended-Release Tablets 1 mg to Xanax XR Tablets 1 mg

To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg

Fasting Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg

Drugs

Nerve Growth Factor

Mecasermin(Increlex)

Alprazolam(Niravam, Xanax)

Organizations

Upjohn EESV

Pharmacia & Upjohn, S.A.

UpJohn US 2 LLC

News

Gland Pharma Receives US FDA Approval for Latanoprost Ophthalmic Solution

Strides Pharma Secures USFDA Approval for Celecoxib Capsules, Targeting $116M Market

Alembic Pharmaceuticals Secures USFDA Approvals for Carbamazepine and Amlodipine-Atorvastatin Generics